Combined Holdings of Verve Therapeutics (VERV) - Updated Daily
Gene TherapyGenomicsCRSPR Gene Editing
Key Statistics
Statistics
| ⚖️Weighting | 🧢Market Cap |
|---|---|
| 0.49% | $913.90m |
| 🏋️♀️Weight Rank Across All Funds | 🌏Country |
| 35 | 🇺🇸United States |
| 💳ARK Estimated Cost Average | 🎫ARK Ownership Percent |
$37.81 - ARKG - ARKK | 6.83% |
| Description | |
|---|---|
| Verve Therapeutics is a biotechnology company created with a singular focus: to protect the world from heart disease. Founded by world-leading experts in cardiovascular medicine, human genetics and gene editing, the company aims to develop transformative, once-and-done therapies for coronary heart disease. Verve’s gene editing medicines are designed to safely edit the genome of adults and mimic naturally occurring gene variants to permanently lower LDL cholesterol and triglyceride levels. The company is advancing a pipeline of precision genetic medicines, led by VERVE-101, which is being developed initially for heterozygous familial hypercholesterolemia, a potentially fatal genetic heart disease. | |
| Website | |
| www.vervetx.com |
Other ETFs That Hold VERV
Research Notes and Commentary for VERV
No Research Notes Found for VERV